Australia markets closed
  • ALL ORDS

    7,490.10
    -178.80 (-2.33%)
     
  • ASX 200

    7,175.80
    -166.60 (-2.27%)
     
  • AUD/USD

    0.7188
    -0.0040 (-0.55%)
     
  • OIL

    85.03
    -0.52 (-0.61%)
     
  • GOLD

    1,832.00
    -10.60 (-0.58%)
     
  • BTC-AUD

    53,520.35
    -6,791.89 (-11.26%)
     
  • CMC Crypto 200

    903.48
    +660.80 (+272.29%)
     
  • AUD/EUR

    0.6333
    -0.0054 (-0.85%)
     
  • AUD/NZD

    1.0693
    -0.0001 (-0.01%)
     
  • NZX 50

    12,348.00
    -149.10 (-1.19%)
     
  • NASDAQ

    14,601.34
    -245.11 (-1.65%)
     
  • FTSE

    7,494.13
    -90.88 (-1.20%)
     
  • Dow Jones

    34,467.83
    -247.56 (-0.71%)
     
  • DAX

    15,603.88
    -308.45 (-1.94%)
     
  • Hang Seng

    24,965.55
    +13.20 (+0.05%)
     
  • NIKKEI 225

    27,522.26
    -250.67 (-0.90%)
     

THERADIAG Announces Its 2022 Financial Calendar

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • ALTER.PA

CROISSY-BEAUBOURG, France, December 08, 2021--(BUSINESS WIRE)--Regulatory News:

THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics of autoimmune diseases and theranostics, today announces its schedule for the publication of financial information for 2022.

Events

Dates*

2021 Full-Year Annual Revenue

Monday January 31, 2022

2021 Full-Year Results

Monday March 21, 2022

Annual General Meeting

Thursday May 5, 2022

2022 First-Half Sales

Monday June 27, 2022

2022 First-Half Results

Monday September 19, 2022

(*) Subject to modifications. Press releases will be published before market open.

About Theradiag

Theradiag is the market leader in biotherapy monitoring. Capitalizing on its expertise in the diagnostics market, the Company has been developing, manufacturing and marketing innovative in vitro diagnostic (IVD) tests for over 30 years.

Theradiag pioneered "theranostics" testing (combining therapy with diagnosis), which measures the efficacy of biotherapy in the treatment of chronic inflammatory diseases. Going beyond mere diagnosis, Theranostics aims to help clinicians set up "customized treatment" for each patient. This method favors the individualization of treatment, evaluation of its efficacy and the prevention of drug resistance. In response to this challenge, Theradiag develops and markets the CE-marked TRACKER® range, a comprehensive solution of inestimable medical value.

The Company is based in Marne-la-Vallée, near Paris, has operations in over 70 countries and employs over 60 people. In 2020, the Company posted revenue of €10.4 million. The Theradiag share is listed on Euronext Growth Paris (ISIN: FR0004197747) and is eligible for the French PEA-PME personal equity plan.

For more information about Theradiag, please visit our website: https://www.theradiag.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20211207006121/en/

Contacts

Theradiag
Bertrand de Castelnau
CEO/Managing Director
Tel.: +33 (0)1 64 62 10 12
contact@theradiag.com

NewCap
Financial Communications & Investor Relations
Pierre Laurent
Quentin Massé
Tel.: +33 (0)1 44 71 94 94
theradiag@newcap.eu

NewCap
Media Relations
Nicolas Mérigeau
Tel.: +33 (0)1 44 71 94 98
nmerigeau@newcap.fr

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting